Thursday, August 28, 2014 1:19:10 PM
Dr. Phillip Frost Leads Investment in Drone Aviation Holding and Is Appointed Chairman of Its Strategic Advisory Board
JACKSONVILLE, FL--(Marketwired - Aug 28, 2014) - Drone Aviation Holding Corp. (OTCQB: DRNE), a developer of specialized tethered drones and lighter-than-air aerostats, today announced that it formed a Strategic Advisory Board that will be headed by Dr. Phillip Frost and that it has accepted subscriptions in a private placement of securities of the Company. Joining Dr. Frost on the newly formed Board is Mr. Steve Rubin.
The Company accepted subscriptions for an aggregate of 1,100,333 shares (the "Shares") of the Company's Series F Convertible Preferred Stock, each of which is convertible into one (1) share of Common Stock of the Company, in a private placement of up to $1,500,000 of its securities to certain accredited investors at a purchase price of $0.75 per Share for an aggregate purchase price of $825,250. Dr. Frost led the investment in the private placement.
"Dr. Frost has a distinguished entrepreneurial track record of success throughout the business community as well as the public marketplace and we are honored to have him Chair our Strategic Advisory Board and as an investor in our Company," stated Felicia Hess, CEO of Drone Aviation Holding Corp. "His extensive government and military relationships during his 13 year tenure as a Director of Northrop Grumman, combined with his capital market expertise, make him an ideal Chairman to lead our newly formed Strategic Advisory Board."
Phillip Frost, M.D. currently serves as the Chairman of the Board and Chief Executive Officer of OPKO Health, Inc., a specialty pharmaceutical company. Additionally, Dr. Frost serves as Chairman of the Board of Directors of TEVA Pharmaceuticals, Ltd., Ladenburg Thalmann Financial Services, Inc. and Prolor Biotech, Inc. and also serves as a Director of Castle Brands, Inc.
Previously, Dr. Frost served as a Director for Northrop Grumman Corp., a global defense company that generates approximately $25 billion in annual revenue and provides technologically advanced, innovative products, services and solutions in systems integration, defense electronics, information technology, advanced aircraft, shipbuilding and space technology. With more than 120,000 employees and operations in all 50 states and 25 countries, Northrop Grumman supplies products and services to the U.S. and international military, government and commercial sectors.
He also previously served as the Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation until its sale to TEVA and Director of Continucare Corp. prior to its sale to Metropolitan Health Networks Inc. Dr. Frost also served on the Board of Directors of IVAX Diagnostic (Chairman) and the American Stock Exchange (Co-Vice Chairman).
Recent OPK News
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 02:10:34 PM
- OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 10:26:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:00:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 06:39:36 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM